ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

LEUPROLIDE ACETATE VERSUS GOSERELIN ACETATE: A RESEARCH STUDY TO ASSESS THE HORMONAL THERAPY EFFECTS ON RELIEF OF LOWER UTI SYMPTOMS, VOLUME REDUCTION AND PROSTATE CANCER

Dr. Muhammad Irfan, Dr. Nageen Waheed, Dr. Ammara Tahir

Background: Lower urinary tract symptoms complaints of the prostate carcinoma (Pca) patients have an association with parallel ageing bladder and benign prostate hyperplasia. Objective: The objective of this research was to highlight and compare the effect of leuprolide acetate with Goserelin acetate on TPV (Total Prostate Volume), PVR (Post Voiding Residue), and Qmax (Maximum Flow Rate Reduction and IPSS (International Prostate Symptom Score) among advanced Pca patients Materials and Methods: This research was carried out at Jinnah Hospital, Lahore from April 2017 to July 2018 on a total of seventy-one patients with Pca. After analysis fifty-one, suitable patients were short-listed and divided into two groups Group A & B respectively treated with Goserelin acetate (10.8 mg) for three months and leuprolide acetate (22.5 mg) for three months. Gleason score, Age, T-stage, pre-treatment and post-treatment PSA (Prostate Specific Antigen), level of testosterone, IPSS, TPV, Qmax and PVR values were documented retrospectively. We also assessed the change in the parameters at an interval of three months. Results: The research included fifty-one patients for assessment process. There was no statistical difference among patients for mean decrease in the percentage of PSA for both groups (Group – A 98.7% and Group – B 98.4%; P-Value = 0.9) and testosterone (Group – A 92.9 % and Group – B 96.4 %; P-Value = 0.15) from baseline to a period of six months; whereas, TPV decreased by (-20.2% ± 4.8) and (-15.6% ± 1.04), the median decrease in the IPSS was (-34.77% ± 8.8) and (-19.77% ± 6.1), the median increase in Qmax was (45.34% ± 10.16) and (23.21% ± 6.93) and median decrease in PVR was (-31.54% ± 8.4) and (-19.23% ± 5.5) for Group – A & B (P-Value < 0.05). Conclusion: The outcomes reflect an improvement in the Goserelin acetate parameters than Leuprolide acetate. The Goserelin acetate superiority based on reduced TPV, IPSS and PVR. Though the time for PSA follow-up was short; but there was no significant difference in the initial oncological findings. Keywords: Prostate Carcinoma (Pca), TPV (Total Prostate Volume), PVR (Post Voiding Residue), Qmax (Maximum Flow Rate), IPSS (International Prostate Symptom Score), Goserelin Acetate and Leuprolide Acetate.

FULL TEXT